The largest database of trusted experimental protocols

Molnupiravir

Manufactured by Merck Group
Sourced in United States, China

Molnupiravir is an investigational antiviral medication that is designed to interfere with the replication of certain viruses, including SARS-CoV-2, the virus that causes COVID-19. It is being developed by Merck & Co., Inc. and Ridgeback Biotherapeutics.

Automatically generated - may contain errors

5 protocols using molnupiravir

1

Molnupiravir and GS-441524 Preparation

Check if the same lab product or an alternative is used in the 5 most similar protocols
molnupiravir (EIDD-2801) and GS-441524 were purchased from Excenen Pharmatech Co., Ltd. (China). For in vitro assays, 10 mM stocks of compounds were made by dissolving in DMSO. For in vivo studies, molnupiravir was formulated as 50 mg/ml stock in a vehicle containing 10% PEG400 (Sigma) and 2.5% Kolliphor-EL (Sigma) in water. GS-441524 was formulated as a 15 mg/ml stock in 30% PEG-400 (Sigma) in PBS containing 1%DMSO.
+ Open protocol
+ Expand
2

Antiviral Drug Preparation and Storage

Check if the same lab product or an alternative is used in the 5 most similar protocols
The antiviral drugs GS-441524, teriflunomide, ritonavir, and nirmatrelvir utilized in this study were purchased from MedChemExpress (Princeton, NJ, USA). Ruxolitinib was obtained from InvivoGen (San Diego, CA, USA), while molnupiravir was sourced from Sigma-Aldrich (St. Louis, MO, USA). The antiviral compounds were dissolved or resuspended in dimethyl sulfoxide to prepare stock solutions (5 mM) of all six drugs. The stock solutions of the drugs were stored at −20 °C for Ruxolitinib and −80 °C for GS-441524, molnupiravir, nirmatrelvir, ritonavir, and teriflunomide. The drugs were further diluted to working concentrations using EMEM medium for experimental use.
+ Open protocol
+ Expand
3

Pharmacokinetics of Molnupiravir and Teriflunomide

Check if the same lab product or an alternative is used in the 5 most similar protocols
Eight-week-old Syrian Gold hamsters (72–96 g) were obtained from Janvier Labs (Saint Berthevin, France). The animals received either 150 mg/kg Molnupiravir (MedChemExpress LLC) twice daily or 20 mg/kg/day Teriflunomide (Biozol) via oral application using a feeding pipet (n = 3 per group). Teriflunomide was formulated in 20% PEG400 (Roth), 2% Tween-80 (Sigma Aldrich), 39% peanut oil (Braendle) and 39% strawberry syrup (Yo); Molnupiravir was formulated in 10% PEG400, 2% Tween-80, 44% water and 44% strawberry syrup. Molnupiravir was given twice daily with 8 h between first and second treatment each day in an application volume of 4 mL/kg. Formulations were freshly prepared before every application. At day one, PK samples were taken 0.5, 1, 2, 4, 8 and 24 h after the first dose. Compound concentrations were analyzed in whole blood using liquid chromatography-mass spectrometry. For Molnupiravir, its active metabolite, EIDD-1931/NHC, was measured.
+ Open protocol
+ Expand
4

Molnupiravir Inhibition of SARS-CoV-2

Check if the same lab product or an alternative is used in the 5 most similar protocols
The effectiveness of NHC was shown in vitro in Calu-3 cells (human lung epithelial cell line) by Rosenke et al. (2021) (link), after 24 h of treatment with NHC. An IC50 of 0.4146 µM was used in the simulations as an inhibitory influence on viral production p, as molnupiravir inhibits viral replication. The proposed dosing regimen was molnupiravir 800 mg every 12 h for 5 days (Merck Sharp & Dohme Corp, 2020 ).
+ Open protocol
+ Expand
5

COVID-19 Treatment in Kidney Transplant Recipients

Check if the same lab product or an alternative is used in the 5 most similar protocols
Nirmatrelvir/ritonavir (Pfizer, USA), azvudine (Henan Zhenzhen Biotechnology, China), and molnupiravir (Merck, USA) are recommended by the National Health Commission for COVID-19 treatment. Ritonavir, a component of nirmatrelvir/ritonavir, is a potent inhibitor of cytochrome P450 3A and P-glycoproteins. After obtaining informed consent from the patients, azvudine and nirmatrelvir/ritonavir were administered to treat KTRs infected with severe COVID-19. Therapeutic drug monitoring was continued during nirmatrelvir/ritonavir treatment, and the restart dose after nirmatrelvir/ritonavir treatment was adjusted accordingly.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!